AcelRx Pharmaceuticals, Inc. ACRX
Set alert
0.86 +0.86 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 14.58M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.10
- Beta
- 0.52
- Short ratio
- 4.56
- Inst. own
- 38.88%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 8, 2023
- 50-d avg
- 0.757638
- 200-d avg
- 0.835636
- 1y target
- 4.63
6M chart
Events in this range
- Aug 10, 2023Earnings: —; estimate -0.53; surprise —%
- Aug 17, 2023Rating: HC Wainwright & Co. · Neutral → Buy
- Nov 8, 2023Earnings: —; estimate -0.29; surprise —%
Signals (27)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Feb 2, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 18, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 16, 2024 | 2 years ago |
| RSI: Overbought | Jan 10, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 9, 2024 | 2 years ago |
| SMA: Bullish | Dec 15, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 12, 2023 | 2 years ago |
| SMA: Bearish | Dec 8, 2023 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| RSI: Overbought | Dec 1, 2023 | 2 years ago |
| RSI: Overbought | Nov 24, 2023 | 2 years ago |
| SMA: Bullish | Nov 21, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 1, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 24, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 9, 2023 | 3 years ago |
| RSI: Oversold | Oct 2, 2023 | 3 years ago |
| RSI: Oversold | Sep 26, 2023 | 3 years ago |
| SMA: Bearish | Sep 7, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 7, 2023 | 3 years ago |
| SMA: Bullish | Aug 29, 2023 | 3 years ago |
Newest 20 of 27.
Analyst view
Consensus: buy
Buy
Price target (mean) 4.63 +438.4% upside
Now 0.86
- Target (low)
- 4.25
- Target (mean)
- 4.63
- Target (high)
- 5.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy0
- Buy3
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 2
- 2 months ago 2
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.18 | -0.21 – -0.16 | -1.00 | +82.0% | 280.00K | +11.1% | 2 |
| Next quarter | -0.24 | -0.24 – -0.24 | -0.75 | +68.0% | 0 | 0.0% | 1 |
| Current year | -1.18 | -1.18 – -1.18 | 5.72 | -120.6% | 510.00K | -71.2% | 1 |
| Next year | -0.78 | -0.78 – -0.78 | -1.18 | +33.9% | 1.36M | +166.7% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2023 | Alliance Global Partners | Initiated | — | Buy |
| Sep 24, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 17, 2023 | HC Wainwright & Co. | Upgrade | Neutral | Buy |